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Summary. Helical strips of saphenous veins from diabetic (n=8)  and non-diabetic 
(n=18) humans were studied in vivo for their responsiveness to several vasoactive 
agents. Following application of passive force (-20.0 mN), venous strips from 
non-diabetic humans often developed spontaneous phasic contractile activity (12 out 
of 18 patients; 2-5 contractions/min). These intrinsic changes in force were seen in 
venous strips from only one diabetic patient. The phasic contractions were not altered 
by treatment with phentolamine, whereas the calcium channel blocker, D-600, and 
calcium-free solution (1 .O mM EGTA) inhibited the phasic contractions. Saphenous 
veins from diabetic patients developed less maximal, active tension in response to 
norepinephrine than those from non-diabetic patients. Contractile responses to 
serotonin, angiotensin 11, and elevated potassium concentration in saphenous veins 
from diabetic patients were not different from those in veins from non-diabetic 
patients. These observations demonstrate attenuated development of active tension in 
response to alpha-adrenergic receptor activation and reduced spontaneous contractile 
activity in venous smooth muscle from diabetic patients. 
Introduction 
Vascular reactivity and structural properties of the blood vessels are altered in 
experimental animal models of diabetes and in diabetic patients (for review see 
Altura, Halevy & Turlapaty, 1979; Chobanian et al., 1982; West 1978). Although the 
experimental procedures vary between different studies (contractility and sensitivity 
to drug action in isolated vascular segments; pressor responsiveness in isolated 
vascular beds; pressor responsiveness in intact animals), it is usually observed that 
vascular responsiveness to angiotensin I1 is exaggerated in the diabetic state (Brody & 
Dixon, 1964; Christlieb et al., 1976; Christlieb, 1974; Kaul & Grewal, 1980), whereas 
vascular responses to catecholomines are either increased (Beretta-Piccoli & 
Weidmann, 1981; Brody & Dixon, 1964; Christlieb et al., 1976; Cseuz et al., 1973; 
Owen & Carrier, 1980; Weidmann et al., 1979, decreased (Joyner et al., 1981; Foy & 
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Lucas, 1976; Sullivan & Sparks, 1979) or unchanged (Christlieb et al.,  1976; 
Christlieb, 1974; Joyner et al., 1981; Kaul & Grewal, 1980) in diabetes compared to 
control values. Augmented pressor responsiveness to angiotensin I1 and nore- 
pinephrine in diabetic patients is correlated with retinopathy (Christlieb et al.,  1976) 
and with mild hypertension (Weidmann et al., 1979). 
The present study was designed to compare contractile responses to vasoactive 
agents in isolated saphenous veins from diabetic patients with those of veins from 
non-diabetic patients. 
Methods 
Saphenous veins from 18 non-diabetic patients and eight patients with diabetes 
mellitus were studied. The non-diabetic group included five females and 13 males 
ranging in age from 48 to 68 years. The diabetic patients included three females and 
five males ranging in age from 51 to 69 years. Diabetes mellitus was diagnosed by 
standard laboratory methods and its known duration ranged from 5 to 14 years (mean 
f standard error of mean (SEM)=8+1 years). All diabetic patients were treated by 
diet andor insulin. None of the diabetic patients had clinically evident retinopathy, 
nephropathy, or autonomic neuropathy. Four of the non-diabetic patients and three 
of the diabetic patients were being treated for hypertension (known duration 8-12 
years; these patients had blood pressures within normal limits at the time of 
experimentation). All patients had been admitted to the hospital for coronary artery 
bypass surgery. 
Following surgery a segment of saphenous vein which was to be discarded was 
obtained and placed in cold physiological salt solution (PSS). The veins were cleaned 
of adherent fat and connective tissue and cut helically into strips (1.5 X 15 mm) under a 
dissecting microscope. Two to 12 strips were cut from each vein. The helical strips 
were mounted vertically on a glass holder in a tissue bath containing PSS. The upper 
ends of the strips were connected to force transducers (Grass FT.03), and the resting 
force placed on each strip was adjusted so that the strip produced maximum active 
force in response to a standard dose of norepinephrine ( 6 . 0 ~ 1 0 - ~  M). The bathing 
medium was maintained at 37°C and aerated with a mixture of 95% O2 and 5% C02. 
The pH of the solution was 7.2 and the composition (mmoV1) was as follows: NaCl 
(130), KC1 (4.7), KH2P04 (1-18), MgS04 7H20 (1-17), CaC12 2H20 (1.6), NaHC03 
(14.9), dextrose (5.5) and CaNa2 EDTA (0.03). Higher concentrations of potassium 
(10-100 mM) in the bathing medium were achieved by equimolar substitution of NaCl 
with KCI. Before the start of experiments, the strips were allowed to equilibrate for 
3 h in PSS. 
Contractile responses to increasing concentrations of agonists (norepinephrine, 
serotonin, angiotensin 11, potassium chloride) were obtained by a cumulative increase 
in the total concentration of the agonist in the bath. The tissue response was allowed 
to reach a stable plateau (2-5 min) before each successive concentration of the agonist 
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was added. Contractile responses to elevated potassium concentrations were 
determined in the presence of 1.3X lop6 M phentolamine to eliminate the effects of 
norepinephrine released from adrenergic nerve endings in the vessel wall (Vanhoutte, 
Verbeuren & Webb, 1981). Norepinephrine and serotonin were dissolved in 0.1% 
ascorbate and serially diluted in distilled water before cumulative addition to the 
muscle bath. Angiotensin I1 was dissolved and serially diluted in distilled water. 
Injection volumes for each drug were 15-35 p1 per dose. Concentrations are expressed 
as molA final concentration in the muscle bath. 
Drugs used were: norepinephrine bitartrate (Sigma Chemical Co.), serotonin 
creatine sulphate (Sigma Chemical Co.), angiotensin I1 (synthetic human form, Sigma 
Chemical Co.), and phentolamine (Ciba Pharmaceuticals). 
The results of these experiments were analyzed by several statistical procedures. 
In all experiments, the multiple strips cut from each vein segment were subjected to 
the same drugs and the responses of the multiple strips were averaged to give a mean 
response for that patient. Thus, the N values reported in the figures and text reflect 
the number of patients in each group. Unless stated otherwise, all reported values are 
the meankstandard error of the mean (SEM). The responses of each venous strip 
were normalized to its cross-sectional area in order to evaluate active tension 
development in response to different agonists between saphenous veins from the two 
patient groups. The cross-sectional area (cm2) of each strip was estimated by dividing 
strip volume in ml (which equals strip weight in g assuming that the density of each 
venous strip is 1.0) by its length in mm at a passive force determined to be optimal for 
maximal force generation in response to norepinephrine (-20.0 mN for all strips). To 
determine the dose of each drug which caused a half-maximal response (EDs0 value), 
the dose-response curves were converted to percent maximal response and -log EDso 
values were determined by a least squares method following logit-log transformation. 
Statistical evaluation of the data was by the Student’s t-test for unpaired samples. Chi 
square analysis was used to compared the incidence of phasic contractile activity 
between groups. A P value less than 0.05 was considered to be statistically significant. 
Results 
CLINICAL VARIABLES 
Compared with the 18 non-diabetic patients, the diabetic patients averaged slightly 
older and tended to have higher plasma glucose levels (Table 1). Heart rates, arterial 
blood pressures and body weights were comparable in the non-diabetic and diabetic 
patients. Plasma creatinine, sodium, potassium and calcium levels, measured under 
basal conditions, were comparable in the two groups (data not shown). 
PHASIC CONTRACTJLE ACTIVITY 
Isolated saphenous vein strips from non-diabetic patients often developed phasic 
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Table 1. Clinical variables in non-diabetic and diabetic patients (mean+SEM) 
Non-diabetic Diabetic 
(n=18; 8 females, 13 males) (n=8; 3 females, 5 males) 
Age (years) 
Body weight (kg) 
Blood pressure (mmHg) 
Heart rate (beatdmin) 
Plasma glucose (mgldl) 
54+2 
81+2 








contractile activity (Fig. 1). These intrinsic changes in force were seen in six strips 
from only one of the diabetic patients (total number of strips=56), whereas these 
changes were seen in 62 strips of 12 of 18 non-diabetic subjects (total number of 
strips=90; Chi square analysis, P<0.05). The frequency of the phasic contractions was 
2-5 responses per 5 min interval and the magnitude of the force generated per 
contraction was comparable in veins from the two groups of patients (non- 
diabetic= 151 f 15 mN/cm2; diabetic= 148f25 mN/cm2). The phasic contractions were 
not altered by treatment with M phentolamine (Fig. 1). The phasic contractions 
were inhibited when the strips were placed in calcium-free PSS containing 1.0 mM 
EGTA but appeared again when normal PSS was returned to the bath. The calcium 
channel blocker, D-600 M), inhibited the phasic contractile responses in a 
reversible manner. 
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Fig. 1. Isometric force recording of an isolated saphenous vein strip from a non-diabetic patient. The top 
tracing illustrates that the phasic contractile responses were not blocked by the alpha-adrenergic 
antagonist, phentolamine ( M). The phasic contractile activity was inhibited by treatment of the strip 
with calcium-free PSS containing 1.0 mM EGTA (middle tracing) and by the calcium channel blocker, 
D-600 M, bottom tracing). 
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Fig. 2. Dose-response to norepinephrine. Helical strips of saphenous veins from non-diabetic patients 
were made to contract in response to the cumulative addition of norepinephrine to the muscle bath. 
Asterisks indicate a statistically significant difference between non-diabetic and diabetic patients 
(Student's r-test, k0.05). Values are the mean+SEM. The values in parentheses are the number of 
patients. 
DOSE-RESPONSES TO NOREPINEPHRINE, SEROTONIN, ANGIOTENSIN I1 AND POTASSIUM 
CHLORIDE 
Cumulative addition of norepinephrine ( 5 . 9 ~  10-"-5.9X lo-' M), serotonin 
( 7 . 8 ~  10-"-2-6x M), angiotensin I1 (10-11-10-5 M) and potassium chloride 
(7.5-100 mM) to the muscle bath produced contractile responses in venous strips from 




Fig. 3. Dose-response to serotonin, antiotensin I1 and potassium chloride. Helical strips of saphenous 
veins from non-diabetic and diabetic patients were made to contract in response to the cumulative 
addition of serotonin (left panel), angiotensin I1 (middle panel) and potassium chloride (right panel). 
Contractile responses to all three agonists in saphenous veins from diabetic patients were not statistically 
different from those in saphenous veins from non-diabetic patients. 
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Table 2. EDsn values and maximal contractile responses 
Maximal tension developed 
EDSO values (M) -log EDSO values ( mN/cm2) 
Diabetic Non-diabetic Diabetic Non-diabetic Diabetic Non diabetic 





Serotonin 2.5X10-' 2.3X10-' 7.609t0.118 
Angiotensin I1 0.2x10-' 0.5x10-* 8-61320.304 

























EDSO values (first two columns) are the anti-log of geometric means presented for respective groups. 
The -log EDSO values were determined following logit-log transformation (see Methods). Values are the 
mean2SEM. The values in parentheses are the number of patients. The asterisk indicates a statistically 
significant difference between patient groups (Student's r-test; R 0 . 0 5 ) .  
norepinephrine and serotonin were determined for all venous strips whereas those for 
angiotensin I1 and potassium chloride were determined in venous strips from five 
diabetic patients and 8-10 non-diabetic patients. Additionally, maximal force 
generation to  100 mM potassium chloride was determined in all venous strips which 
were not characterized by the cumulative dose-effect of this contractile agonist. 
Maximal tension developed in response to norepinephrine was decreased in 
saphenous veins from diabetic patients compared to that in veins from non-diabetic 
patients (Fig. 2 and Table 2). Saphenous veins from diabetic patients also developed 
consistently less maximal tension in response to serotonin (Fig. 3 and Table 2) than 
those from non-diabetic patients although this difference was not significantly 
different on a statistical basis. Maximal tension developed in response to angiotensin 
I1 and potassium chloride in saphenous veins from five diabetic patients was not 
statistically different from that in veins from 8-10 non-diabetic patients (Fig. 3 and 
Table 2). In these experiments which examined contractile effects of angiotensin I1 
and serotonin, the venous strips from diabetic patients showed significantly reduced 
maximal responses to norepinephrine (1 141f253 mN/cm2; n=5) but not to serotonin 
(1791f565 mN/cm2; n=5) compared to that in venous strips from non-diabetic 
patients (2473f575 mN/cm2; 2180f595 mN/cm2, respectively; n=10) suggesting that 
these experiments did not constitute a clinically relevant subgroup. Maximal tension 
development to 100 mM potassium chloride for venous segments from diabetic 
patients not used in the dose-relationship analysis (1385f296 mN/cm2; n=3) was not 
statistically different from that in similar venous segments from nondiabetic patients 
(1403f126 mN/cm2; n=10). Maximal tension to potassium chloride in strips used for 
determining the dose-dependent effects of the contractile agonist did not differ from 
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these values determined by single dose analysis (compare above values with those 
reported in Table 2 ) .  Grouping the observations for maximal tension to potassium 
chloride from both experimental determinations yielded the following average values: 
diabetic patients (n=8)=1481k 173 mN/cm2; non-diabetic patients (n=18)=1461+94 
mN/cm2 (P> 0-05) .  
In order to compare sensitivity to the agonists between the two patient groups, the 
values reported in Figs 2 and 3 were normalized to per cent maximal response and the 
dose of the agonist producing a half maximal response was calculated. The doses of 
each drug which produced half-maximal responses (-log EDs0 values) in saphenous 
veins from diabetic patients were not statistically different from those in veins from 
non-diabetic patients (Table 2) .  
As reported in the Methods section, several of the patients involved in this study 
were being treated for hypertension (four non-diabetic patients and three diabetic 
patients). Contractile responses of vein segments from these subjects were not 
significantly different from those of other venous strips within their respective 
subgroups (data not shown). 
Discussion 
Experimental evidence suggests that the responsiveness of the vasculature in diabetes 
to vasoactive drugs is altered compared to that in controls (for review, see Altura, 
Halevy & Turlapaty, 1979; Chobanian et al., 1982; West, 1978). The observations of 
different studies are highly variable suggesting that reported differences may be 
influenced by the following: ( 1 )  animal species; ( 2 )  in vivo versus in vitro conditions; 
( 3 )  resistance vessel versus large vessel differences; ( 4 )  the type of diabetes 
(experimental (streptozotocin-induced versus alloxan-induced) versus clinical); ( 5 )  
the duration and/or severity of the diabetic state; and ( 6 )  the vasoactive agents tested. 
To our knowledge, this is the first study that characterizes smooth muscle reactivity in 
isolated vascular segments from diabetic patients. 
Saphenous veins from diabetic patients developed less maximal tension in 
response to norepinephrine than those from non-diabetic patients. Maximal tension 
development to seroronin in veins from diabetic patients was consistently less than 
that in veins from non-diabetic patients but the difference was not statistically 
significant. The cellular mechanism leading to this depressed maximal response to 
norepinephrine in diabetes is unclear. The diabetic venous strips were not at a lower 
point on their length-tension curve than those from non-diabetic patients. The 
optimum passive force for maximum response to norepinephrine was similar for 
venous strips from diabetic and non-diabetic patients (-20.0 mN). Furthermore, a 
difference in the length-tension relationship would be predicted to result in a 
generalized change in contractility. Since smooth muscle reactivity to angiotensin I1 
and potassium chloride in saphenous veins from diabetic patients was not statistically 
different from that in veins from non-diabetic patients, the results suggest that a 
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specific change in force-generating ability in response to alpha-adrenergic receptor 
activation (and possibly serotonergic receptor activation) occurs in veins from diabetic 
patients. 
One possible cause of the difference in adrenergic responsiveness in diabetic veins 
is an increase in the neuronal uptake mechanism of nerve endings present in the blood 
vessel wall. Neuronal uptake of norepinephrine plays a role in catecholamine 
disposition (Vanhoutte, Verbeuren & Webb, 1981; Webb, Vanhoutee & Bohr, 1980) 
and an increase in its activity could decrease receptor activation producing reduced 
contractile responses. This seems unlikely since changes in neuronal uptake activity 
are not usually accompanied by altered maximum force-generating ability (Van- 
houtte, Verbeuren & Webb, 1981; Webb, Vanhoutte & Bohr 1980) and changes in 
the function of adrenergic nerves are usually associated with changes in catecholomine 
sensitivity (Bevan, Bevan & Duckles, 1980; Vanhoutte, Verbeuren & Webb, 1981; 
Webb, Vanhoutte & Bohr, 1980). The sensitivity (-log EDsa values) to norepine- 
phrine of saphenous vein strips from diabetic patients was not statistically different 
from that in veins from non-diabetic patients (Table 2). 
Another possible explanation for reduced adrenergic responsiveness of venous 
strips from diabetic patients is an increased beta-adrenergic component. Contractile 
responses to norepinephrine are the sum of alpha-adrenergic receptor-mediated 
contraction and beta-receptor mediated-relaxation. An increased beta receptor- 
mediated component could result in a reduced contractile response if the number and 
affinity of alpha-adrenergic receptors remained constant. This seems an unlikely 
explanation since increased beta-adrenegic activity would probably decrease alpha- 
adrenergic sensitivity (rightward shift in the normalized dose-response curve; Bevan, 
Bevan & Duckles, 1980). 
It seems likely that the decreased maximum force generating ability of venous 
strips from diabetic patients to norepinephrine is caused by a reduction in some 
component of the contractile sequence following alpha-receptor activation. The basis 
for this conclusion is that contractile responses to the agonists used in this study 
depend on different mechanisms to produce contraction. For example, elevated 
potassium concentration causes membrane depolarization, and the contractile 
response is the result of an influx of extracellular calcium into the cell (Bohr, 1973; 
Weiss, 1981). In contrast, norepinephrine-induced contractions are caused by an 
initial release of intracellularly bound calcium followed by an increased cellular 
membrane permeability to the cation. Based on studies with calcium channel blockers 
(Bohr, 1973; Weiss, 1981), it is likely that the calcium channels opened by a change in 
membrane potentinal are different from those opened in response to alpha-adrenergic 
receptor activation. A reduction in the number of calcium channels opened by 
alpha-adrenergic receptor activation may explain reduced maximal force generation 
to norepinephrine in saphenous veins from diabetic patients. 
In the present study, saphenous vein strips from non-diabetic patients exhibited a 
greater incidence of spontaneous phasic contractile activity than did those from 
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diabetic patients. These phasic contractions were not blocked by phentolomine, 
suggesting that the contractions were not caused by leakage of norepinephrine from 
adrenergic nerve endings in the vessel wall. Calcium-free solution containing EGTA 
and the calcium channel blocker, D-600, abolished the phasic contractions. The 
magnitude of the phasic contractile responses in saphenous veins from the diabetic 
patient were not different from those in veins from non-diabetic patients. Since the 
incidence of these calcium-dependent contractions are reduced in diabetes, these 
observations provide further evidence for a change in calcium handling by the cellular 
membrane of smooth muscle cells in saphenous veins from diabetic patients. 
References 
ALTURA B. M., HALEVY S. & TURLAPATY P. D. M. V. (1979) Vascular smooth muscle in diabetes and its 
influence on the reactivity of blood vessels. Adv Microcir. 8, 118-150. 
BERETTA-PICCOLI C. & WEIDMANN P. (1981) Exaggerated pressor responsiveness to norepinephrine in 
nonazotemic diabetes mellitus. Am J Med, 71, 829-835. 
BEVAN J. A., BEVAN R. D. & DUCKLES S. P. (1980) Adrenergic regulation of vascular smooth muscle. In: 
Handbook of Physiology, The Cardiovascular System. Sec 2, Vol II (eds. Bohr D.  F., Somlyo A. P. & 
Sparks H.  V. Jr.),  pp. 515-566. Physiol SOC, Bethesda, MD, U.S.A. 
BOHR D. F. (1973) Vascular smooth muscle updated. Circulation Res, 32, 66-72, 
BRODY M. J & DIXON R. L. (1964) Vascular reactivity in experimental diabetes mellitus. Circulation Res, 
CHRISTLIEB A. R. (1974) Renin, angiotensin and norepinephrine in alloxan diabetes. Diabetes, 23,962-970. 
CHRISTLIEB A. R., JANKA H.-V., KRAUS B., GLEASON R. E., KASAS-COBRAL E. A,,  AIELLO L. M.,  CABRAL 
B. R. & SOLANO A. (1976) Vascular reactivity to angiotensin II  and to norepinephrine in diabetic 
subjects. Diabetes, 25, 268-274. 
CHOBANIAN A. V., ARQUILLA E. R.. CLARKSON T. R., EDER H.  A , ,  HOWARD C. F., REGAN T.  J. & 
WILLIAMSON J .  R. (1982) Cardiovascular complications. Diabetes. 31 (Suppl. 1). 54-64. 
CSEUZ R., WENGER T. L., KUNAS G. & SZENTIVANY M. (1973) Changes of adrenergic reaction pattern in 
experimental diabetes mellitus. Endocrinology, 93, 752-755. 
FOY J.  M. & LUCAS P. D. (1976) Effect of experimental diabetes, food deprivation and genetic obesity on 
the sensitivity of pithed rats to autonomic agents. Br J Pharmac. 57, 229-234. 
JOYNER W. L.. MAYHAN W. G., JOHNSON R. L. & PHARES C. K. (1981) Microvascular alterations develop in 
Syrian hamsters after the induction of diabetes mellitus by streptozotocin. Diabetes, 30, 98-100. 
KAUL C. L. & GREWAI. R. S. (1980) Vascular reactivity in streptozotocin induced diabetic rats. Pharmac 
Res Commun, 12, 945-958. 
OWEN M. P. & CARRIER G. 0. (1980) Calcium dependence of norepinphrine-induced vascular contraction 
in experimental diabetes. J Pharmacol exp Ther. 212, 253-258. 
SULLIVAN S. & SPARKS H. V. (1979) Diminished contractile response of aortas from diabetic rabbits. Am I 
VANHOUTTE P. M., VERBEUREN T. J .  & WEBB R. C. (1981) Local modulation of the adrenergic 
neuroeffector interaction in the blood vessel wall. Physiol Rev, 61, 151-247. 
WEBB R. C., VANHOUITE P. M. & BOHR D. F. (1980) Inactivation of released norepinephrine in rat tail 
artery by neuromal uptake. J Cardiovusc Pharmacol, 2, 121-132. 
WEIDMANN P., BERETTA-PICCOLI C.,  KEUSCH G., GLUCK Z., MUJAGIC M.. GRIMM ., MEIR A.  & ZIEGLER 
W. H. (1979) Sodium-volume factors, cardiovascular reactivity and hypotensive mechanism of diuretic 
therapy in mild hypertension associated with diabetes mellitus. A m  J Med 67, 77Y-784. 
14, 494-501. 
Physiol, 236, H301-H306. 
WEISS G .  B. (1981) New Perspectives on Calcium Antagonists. Waverly Press, Baltimore. 
WEST K. M. (1978) Epidemiology of Diabetes and its Vascular Lesions. ElseviedNorth Holland Biomedical 
Press. Amsterdam. 
